Export financials
Bioventus (BVS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Bioventus Cash Flow 2025-2011 | BVS
Brief cash flow overview of Bioventus
The comparison covers five available annual reports between 2021 and 2025.
Operating cash flow advanced from $23 million to $74.7 million. A +224.8% gain and 34.2% CAGR show rapidly improving cash generation.
Operating cash flow was above zero 4 times out of five. Most, but not all, periods generated cash.
Operating cash margin reached 13.1% versus 5.3% initially. Revenue converted into cash more effectively.
Receivables and inventory net of payables grew by $29.9 million, absorbing resources equal to about 5.3% of revenue.
Cash flow takeaway
Bioventus 's cash generation remains workable and supports the business, though some uses of cash limit flexibility.
Annual Cash Flow Bioventus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
74.7 M | 38.8 M | 15.3 M | -13.5 M | 23 M | 71.8 M | 40.7 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
47 M | 49.6 M | 57.4 M | 55.4 M | 34.9 M | 28.6 M | 30.3 M | - | - | - | - | - | - | - | - |
Accounts Payables |
10.9 M | 23.7 M | 23 M | 36.7 M | 16.9 M | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
128 M | 127 M | 123 M | 136 M | 125 M | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
82.2 M | 92.5 M | 91.3 M | 84.8 M | 61.7 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Bioventus
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
28.8 M | 8.93 M | - | - | -19.3 M | - | - | -6 M | - | - | 2.49 M | - | -18.8 M | -18.1 M | -21 M | - | 9.87 M | -713 K | -18 M | - | 46.4 M | 25.5 M | 17.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
22.2 M | 11.2 M | 1.4 M | 1.44 M | 11.9 M | 2.06 M | 2.06 M | 11.8 M | 2.32 M | 2.29 M | 16.5 M | - | 2.26 M | 2.7 M | 12.5 M | - | 23.2 M | 14.7 M | 7.18 M | - | 21.8 M | 14.5 M | 7.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
20.2 M | 24 M | 26.6 M | 24.2 M | 19.2 M | 16.8 M | 24.4 M | 19.1 M | 17.6 M | 41.4 M | 32.8 M | 36.7 M | 19.1 M | 25.7 M | 22.5 M | 16.9 M | 10.9 M | 9.88 M | 10.3 M | 4.42 M | 4.42 M | 4.42 M | 4.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
138 M | 121 M | 130 M | 132 M | 118 M | 122 M | 137 M | 126 M | 113 M | 120 M | 119 M | 136 M | 132 M | 143 M | 119 M | 125 M | 105 M | 102 M | 89.5 M | 88.3 M | 88.3 M | 88.3 M | 88.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
79.8 M | 83.2 M | 96.3 M | 96.5 M | 94 M | 90 M | 87.6 M | 97 M | 97.6 M | 96.3 M | 88 M | 84.8 M | 77 M | 69.1 M | 64.7 M | 61.7 M | 36.6 M | 34 M | 39.8 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Bioventus , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B | ||
|
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | ||
|
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | ||
|
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | ||
|
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | ||
|
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | ||
|
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | ||
|
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B | ||
|
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | ||
|
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | ||
|
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | ||
|
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | ||
|
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B | ||
|
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | ||
|
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | ||
|
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | ||
|
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | ||
|
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | ||
|
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | ||
|
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | ||
|
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | ||
|
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | ||
|
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | ||
|
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | ||
|
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M | ||
|
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | ||
|
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M | ||
|
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M |